JP2013528622A5 - - Google Patents

Download PDF

Info

Publication number
JP2013528622A5
JP2013528622A5 JP2013513360A JP2013513360A JP2013528622A5 JP 2013528622 A5 JP2013528622 A5 JP 2013528622A5 JP 2013513360 A JP2013513360 A JP 2013513360A JP 2013513360 A JP2013513360 A JP 2013513360A JP 2013528622 A5 JP2013528622 A5 JP 2013528622A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cadherin
optionally
composition according
der
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013513360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528622A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/039002 external-priority patent/WO2011153397A2/en
Publication of JP2013528622A publication Critical patent/JP2013528622A/ja
Publication of JP2013528622A5 publication Critical patent/JP2013528622A5/ja
Pending legal-status Critical Current

Links

JP2013513360A 2010-06-04 2011-06-03 炎症性障害の処置 Pending JP2013528622A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35150510P 2010-06-04 2010-06-04
US61/351,505 2010-06-04
PCT/US2011/039002 WO2011153397A2 (en) 2010-06-04 2011-06-03 Treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
JP2013528622A JP2013528622A (ja) 2013-07-11
JP2013528622A5 true JP2013528622A5 (https=) 2014-07-24

Family

ID=45067307

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013513360A Pending JP2013528622A (ja) 2010-06-04 2011-06-03 炎症性障害の処置

Country Status (7)

Country Link
US (1) US20130209476A1 (https=)
EP (1) EP2575883B1 (https=)
JP (1) JP2013528622A (https=)
AU (1) AU2011261323A1 (https=)
CA (1) CA2805270C (https=)
IL (1) IL223385B (https=)
WO (1) WO2011153397A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130068691A1 (en) * 2011-08-05 2013-03-21 Henry John Smith Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders
WO2016100301A1 (en) * 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
US20200181649A1 (en) * 2016-07-14 2020-06-11 University Of Delaware Hybrid formulation of responsive polymeric nanocarriers for therapeutic and diagnostic delivery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
US7481999B2 (en) * 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
US6787136B1 (en) * 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
CN101613406A (zh) * 2002-06-06 2009-12-30 肿瘤疗法科学股份有限公司 与人结肠癌相关的基因和多肽
CN101318019B (zh) * 2003-04-23 2012-08-29 梅达雷克斯公司 含1型干扰素拮抗剂的组合物及其在制备治疗炎症性肠病的药物中的用途
WO2005007175A2 (en) * 2003-06-09 2005-01-27 The Brigham And Women's Hospital, Inc. Cadherin directed molecular and cellular localization
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
AU2008251877A1 (en) * 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
US20100322926A1 (en) * 2008-02-11 2010-12-23 Novartis Ag Methods of using cadherin 11 (cdh11) antagonists
EP3372591B1 (en) * 2009-02-09 2021-05-26 Georgetown University Cadherin-11 inhibitors and methods of use thereof
KR20130107203A (ko) * 2010-05-04 2013-10-01 더 브리검 앤드 우먼즈 하스피털, 인크. 섬유증의 검출 및 치료
US8877188B2 (en) * 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis

Similar Documents

Publication Publication Date Title
Qu et al. Stimulation of sigma‐1 receptor protects against cardiac fibrosis by alleviating IRE1 pathway and autophagy impairment
van Koppen et al. Human embryonic mesenchymal stem cell-derived conditioned medium rescues kidney function in rats with established chronic kidney disease
Matsumoto et al. CD44 expression in astrocytes and microglia is associated with ALS progression in a mouse model
Yang et al. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats
JP2014526441A5 (https=)
JP2016517888A5 (https=)
Momcilović et al. CXCL12 in control of neuroinflammation
US20230129866A1 (en) Methods of treating respiratory disease with deupirfenidone
WO2021183774A1 (en) Treating acute respiratory distress
JP2013528622A5 (https=)
Su et al. Silencing of RSPO1 mitigates obesity-related renal fibrosis in mice by deactivating Wnt/β-catenin pathway
Ai et al. Paeonol ameliorates diabetic nephropathy by promoting TFEB-mediated lysosome biogenesis and lipophagy
Garcia-Dorado et al. Primary results of the PROMISE trial: myocardial protection with intracoronary adenosine given before reperfusion in patients with STEMI
Govaert et al. Poor functional recovery after transplantation of diabetic bone marrow stem cells in ischemic myocardium
van Echteld et al. A view on imaging in drug research and development for respiratory diseases
Wesseling et al. Mildly increased renin expression in the absence of kidney injury in the murine transverse aortic constriction model
CN106714842A (zh) 包含双重PI3K δ‑γ激酶抑制剂和皮质类固醇的治疗方法及组合物
Sababathy et al. A ‘One Stone, Two Birds’ Approach with Mesenchymal Stem Cells for Acute Respiratory Distress Syndrome and Type Ii Diabetes Mellitus
JP2018500882A5 (https=)
CN104644620B (zh) 化合物xl‑001在制备治疗慢性肾脏病的药物中的用途
JP2014079188A (ja) 無菌性慢性前立腺炎非ヒトモデル動物、頻尿非ヒトモデル動物およびこれらを用いた被験物質の評価方法
Church et al. The artificial placenta rescues premature lambs from Ventilatory failure
Suda et al. Spherical sulfated cellulose adsorbs high-mobility-group box chromosomal protein 1 in vitro and in vivo
Lieberman et al. Preliminary Findings from the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients with Selected Proteinuric Glomerular Diseases: SA-OR84
Cuijpers A novel paradigm for heart failure with preserved ejection fraction: Working towards understanding the pathology of HFpEF